4502.T
現在値
4,320.00JPY変化
-49.00(-1.12%)出来高
4,663,900本日のレンジ
-
4,330.0052週レンジ
-
4,478.00∙ 約20分前の相場を表示しています。
March 23 (Reuters) - Takeda Pharmaceutical Co <4502.T>: :*TO INVEST 100 BILLION YEN ($762.60 million) IN A NEW MANUFACTURING FACILITY FOR PLASMA-DERIVED THERAPIES IN JAPAN*INVESTMENT IS ITS LARGEST EVER FOR MANUFACTURING CAPACITY EXPANSION IN JAPAN.
March 23 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL TO INVEST ABOUT 100 BILLION YEN TO BUILD A NEW PLANT IN OSAKA TO PRODUCE PLASMA DERIVATIVES - NIKKEI.
Feb 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PRESENTS POSITIVE RESULTS FROM PHASE 3 STUDY OF VEDOLIZUMAB FOR PREVENTION OF INTESTINAL ACUTE GRAFT-VERSUS-HOST DISEASE (AGVHD) IN PATIENTS UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO-HSCT).TAKEDA- PHASE 3 GRAPHITE STUDY MET ITS PRIMARY EFFICACY ENDPOINT OF SIGNIFICANT, CLINICALLY MEANINGFUL INTESTINAL AGVHD-FREE SURVIVAL.
Feb 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA UK LTD. ANNOUNCES MHRA APPROVAL FOR DENGUE VIRUS VACCINE CANDIDATE QDENGA®▼.TAKEDA UK LTD. - EXPECTS TO MAKE QDENGA® AVAILABLE IN UK IN SPRING/SUMMER 2023.
Feb 3 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::U.S. FDA APPROVES TAKEDA’S TAKHZYRO® (LANADELUMAB-FLYO) TO PREVENT HEREDITARY ANGIOEDEMA (HAE) ATTACKS IN CHILDREN 2 YEARS OF AGE AND OLDER.TAKEDA PHARMACEUTICAL-APPROVAL SUPPORTED BY EXTRAPOLATION OF EFFICACY DATA FROM PHASE 3 HELP STUDY WITH ADDITIONAL DATA FROM PHASE 3 SPRING STUDY.
Jan 23 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA TO ACQUIRE EXCLUSIVE WORLDWIDE (EX-CHINA) LICENSE OF HUTCHMED’S FRUQUINTINIB, A HIGHLY SELECTIVE, ORAL VEGFR1/2/3 TYROSINE KINASE INHIBITOR.CO WILL PAY HUTCHMED $400 MILLION UPFRONT, UP TO $730 MILLION IN ADDITIONAL POTENTIAL PAYMENTS.
Jan 9 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA PHARMACEUTICAL CO LTD -.ARROWHEAD AND TAKEDA ANNOUNCE TOPLINE RESULTS FROM SEQUOIA PHASE 2 STUDY OF FAZIRSIRAN IN PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY-ASSOCIATED LIVER DISEASE.TAKEDA PHARMACEUTICAL CO LTD - TREATMENT EMERGENT ADVERSE EVENTS WERE GENERALLY WELL BALANCED BETWEEN FAZIRSIRAN AND PLACEBO GROUPS.TAKEDA PHARMACEUTICAL CO LTD - FIBROSIS REGRESSION OBSERVED IN 50% OF PATIENTS RECEIVING FAZIRSIRAN.
Jan 5 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA ANNOUNCES FAVORABLE PHASE 3 SAFETY AND EFFICACY RESULTS OF TAK-755 AS COMPARED TO STANDARD OF CARE IN CONGENITAL THROMBOTIC THROMBOCYTOPENIC PURPURA (CTTP).TAKEDA PHARMACEUTICAL CO LTD - TAKEDA PLANS TO SEEK MARKETING AUTHORIZATION FOR TAK-755 AS FIRST ADAMTS13 REPLACEMENT THERAPY FOR TREATMENT OF CTTP.TAKEDA- RESULTS FROM INTERIM ANALYSIS OF PHASE 3 STUDY HAVE NO IMPACT ON FY CONSOLIDATED REPORTED FORECAST FOR FISCAL YEAR ENDING MARCH 31, 2023.
Dec 13 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA TO ACQUIRE LATE-STAGE, POTENTIAL BEST-IN-CLASS, ORAL ALLOSTERIC TYK2 INHIBITOR NDI-034858 FROM NIMBUS THERAPEUTICS.TAKEDA - WILL PAY NIMBUS $4B UPFRONT, TWO MILESTONE PAYMENTS OF $1B EACH UPON ACHIEVING ANNUAL NET SALES OF $4B AND $5B.
Dec 8 (Reuters) - :EUROPEAN HEALTH REGULATORS CLEARED A NEW DENGUE VACCINE FROM TAKEDA PHARMACEUTICAL CO - WSJ.THE EUROPEAN COMMISSION APPROVED THE TWO-DOSE SHOT IN PEOPLE AGES 4 YEARS AND OLDER, TAKEDA SAID - WSJ.
金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。